Skip to main content
SpringerLink
Log in

Antianämika

  • Chapter
Arzneiverordnungs-Report 2007

  • 562 Accesses

Auszug

Der größte Teil der Verordnungen von Antianämika entfällt weiterhin auf Eisenpräparate, die bis auf eine Ausnahme nur noch als Monopräparate verordnet werden. An zweiter Stelle folgen die Epoetinpräparate, während die rezeptfreie Folsäure zahlenmäßig eine untergeordnete Rolle spielt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  • American Medical Association (1986): Drug evaluations (6th Edition). Saunders Company Philadelphia, London, pp. 589–601.

    Google Scholar 

  • Baker WF, Bick RL (1999): Treatment of hereditary and acquired thrombophilic disorders. Semin Thromb Hemost 25: 387–406.

    Article  PubMed  CAS  Google Scholar 

  • Begemann H, Rastetter J (Hrsg) (1993): Klinische Hämatologie, Kapitel “Anämien”. Georg-Thieme-Verlag Stuttgart, New York, S. 237–418.

    Google Scholar 

  • Besarab A, Bolton WK, Browne JK, Egrie, JC, Nissenson AR et al (1998): The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584–590.

    Article  PubMed  CAS  Google Scholar 

  • Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, Engert A (2005): Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 97: 489–498.

    Article  PubMed  CAS  Google Scholar 

  • Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A et al (NORVIT Trial Investigators) (2006): Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354: 1578–1588.

    Article  PubMed  CAS  Google Scholar 

  • Boven K, Knight J, Bader F, Rossert J, Eckardt KU, Casadevall N (2005): Epoetinassociated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant 20,Suppl 3: iii33–40.

    Article  PubMed  CAS  Google Scholar 

  • Büchner T (2003): Anämien. In: Therapie Innerer Krankheiten (Hrsg Paumgartner G, Steinbeck G). Springer-Verlag Berlin, Heidelberg, New York, 10. Aufl., S. 1015.

    Google Scholar 

  • Collins AJ, Ma JZ, Xia A, Ebben J (1998): Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis 32(Suppl 4): S133–S141.

    Article  PubMed  CAS  Google Scholar 

  • Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Mcdougall IC et al (2006): Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071–2084.

    Article  PubMed  Google Scholar 

  • Dührsen U (2002): Gibt es Indikationen für Erythropoetin in der Onkologie? Dtsch Ärztebl 99: A3470–A3475.

    Google Scholar 

  • Fishbane S (2003): Safety in iron management. Am J Kidney Dis 41(5 Suppl): 18–26.

    Article  PubMed  Google Scholar 

  • Fishbane S, Mittal SK, Maesaka JK (1999): Beneficial effects of iron therapy in renal failure patients on hemodialysis. Kidney Int 55: 67–70.

    Article  Google Scholar 

  • Food and Drug Administration (2007): Information for Healthcare Professionals March 9, 2007. Erythropoesis stimulating agents (ESA). Internet: www.fda.gov/ cder/drug/InfoSheets/HCP/RHE2007HCP.pdf

    Google Scholar 

  • Hanley DF (2004): The challenge of stroke prevention. JAMA 291: 621–622.

    Article  PubMed  CAS  Google Scholar 

  • Heinrich HC (1986): Bioverfügbarkeit und therapeutischer Wert oraler Eisen(II)-und Eisen(III)-Präparate. Dtsch Apoth Ztg 126: 681–690.

    Google Scholar 

  • Henke M, Laszig R, Rübe C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H (2003): Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362: 1255–1260.

    Article  PubMed  CAS  Google Scholar 

  • Homocysteine Studies Collaboration (2002): Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288: 2015–2022.

    Article  Google Scholar 

  • Hörl WH, Vanrenterghem Y (2005): Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin. NephrolDialTransplant 20, Suppl.3: iii25–32.

    Google Scholar 

  • Ibbotson T, Goa KL (2001): Darbepoetin alfa. Drugs 61: 2097–2104.

    Article  PubMed  CAS  Google Scholar 

  • Kaltwasser JP (2003): Eisenmangelanämie. In: Berdel WE, Böhm M, Classen M, Diehl V, Kochsiek K, Schmigel W (Hrsg): Innere Medizin. 5. Auflage, Urban & Fischer, München Jena, S. 706–711.

    Google Scholar 

  • Kaltwasser JP, Werner E, Niechzial M (1987): Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations. Arzneim Forsch 37: 122–129.

    CAS  Google Scholar 

  • Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG et al (1998): Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 339: 578–583.

    Article  PubMed  CAS  Google Scholar 

  • Khuri FR (2007): Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 356: 2445–2448.

    Article  PubMed  CAS  Google Scholar 

  • Koletzko B, Pietrzik K (2004): Gesundheitliche Bedeutung der Folsäurezufuhr. Dtsch Ärztebl 101: A 1670–1681.

    Google Scholar 

  • Lange H, Suryapranata H, De Luca G, Böner C, Dille J, Kallmayer K et al (2004): Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 350: 2673–2681.

    Article  PubMed  CAS  Google Scholar 

  • Leyland-Jones B; BEST Investigators and Study Group (2003): Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4: 459–460.

    Article  PubMed  Google Scholar 

  • MacDougall IC (1999): Strategies for iron supplementation: Oral versus intravenous. Kidney Int 55: 61–66.

    Article  Google Scholar 

  • Marsh WA, Rascati KL (1999): Meta-analyses of the effectiveness of erythropoetin for end-stage renal disease and cancer. Clin Ther 21: 1443–1455.

    Article  PubMed  CAS  Google Scholar 

  • Michael B, Coyne DW, Fishbane S, Folkert V, Lynn R, Nissenson AR et al (2002): Sodium ferric gluconate complex in hemodialysis patients adverse reactions compared to placebo nd iron dextran. Kidney Int 61: 1830–1839.

    Article  PubMed  CAS  Google Scholar 

  • O’Riordan E, Foley RN (2001): When should we start erythropoietin therapy? Nephrol Dial Transplant 16: 891–892.

    Article  PubMed  CAS  Google Scholar 

  • Queißer-Luft A, Spranger J (2006): Fehlbildungen bei Neugeborenen. Dtsch Ärztebl 103: C2060–2066.

    Google Scholar 

  • Rothenberg SP, da Costa MP, Sequeira JM, Cracco J, Roberts JL et al (2004): Autoantibodies against folate receptors in women with a pregnancy complicated by a neural-tube defect. N Engl J Med 350: 134–142.

    Article  PubMed  CAS  Google Scholar 

  • Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S et al (2006): Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085–2098.

    Article  PubMed  CAS  Google Scholar 

  • Tentori L, Graziani G (2007): Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk? Pharmacol Res 55: 359–369.

    Article  PubMed  CAS  Google Scholar 

  • The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators (2006): Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354: 1567–1577.

    Article  Google Scholar 

  • Thomas L, Thomas C, Heimpel H (2005): Neue Parameter zur Diagnostik von Eisenmangelzuständen. Dtsch Ärztebl 102: A 580–586.

    Google Scholar 

  • Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC et al (2004): Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarktion, and death: the vitamin intervention for stroke prevention (VISP). JAMA 291: 565–575.

    Article  PubMed  CAS  Google Scholar 

  • Wald NJ (2004): Folic acid and the prevention of neural-tube defects. N Engl J Med 350: 101–103.

    Article  PubMed  CAS  Google Scholar 

  • Weiss LG, Clyne N, Divino Fihlho J, Frisenette-Fich C, Kurkus J, Svensson B (2000): The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin ß: results from a randomized controlled multicentre trial. Swedish Study Group. Nephrol Dial Transplant 15: 2014–2019.

    Article  PubMed  CAS  Google Scholar 

  • Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, Bayliss S, Moss P, Stanworth S, Hyde C (2007): A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 11: 1–220.

    PubMed  CAS  Google Scholar 

  • Wollenberg P (2005): Eisen — Pharmakotherapie des Eisenmangels. In: Allgemeine und spezielle Pharmakologie und Toxikologie (Hrsg. Aktories K, Förstermann U, Hofmann F, Starke K) Urban & Fischer Verlag München, Jena, 9. Aufl., S. 737–747.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Höferstraße 15, 68199, Mannheim

    Dr. med. Klaus Mengel

Authors
  1. Dr. med. Klaus Mengel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK Schleswig-Holstein Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Mengel, K. (2008). Antianämika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2007. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-72548-0_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-72548-0_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-72547-3

  • Online ISBN: 978-3-540-72548-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation